2nd Abu Dhabi Brain Conference 2022 Program Book

Date of preparation: September 2021 151677 Aimovig (erenumab) is indicated for prophylaxis of migraine in adults. 1 AIMOVIG. SUSTAINEDMIGRAINE PREVENTION. GIVE THEMBACKTHEIR DAYS ANDWEEKS, YEARAFTERYEAR. AIMOVIG IS THE MOST PRESCRIBED ANTI CGRP WORLDWIDE AND IN THE UAE 600,000 PATIENTS WORLD WIDE MORE THAN 1 2 Novartis Middle East FZE P.O. Box: 23510, Dubai- United Arab Emirates Tel: +97144357094 - Fax: +971144357701 www.novartis.com References: 1. IQVIA Local Market Share data as of September 2021 2. https://www.novartis.com/sites/www.novartis.com/files/2021-10-interim-financial-report-en.pdf 3. BMC Neurology Journal (Targeted Journal) – Data on File (DOF) ≥50 % Up to 95% of patients achieve ≥ 50% reduction in MMDs at month 6 3 95 % Important note: Before prescribing, consult full prescribing information. Composition: Solution for injection for subcutaneous use 1 pre-filled pen of 1 ml contains 70 mg or 140 mg of Erenumab. Indication: Prophylactic treatment of migraines in adults, if indicated. Dosage and Administration: One Aimovig dose of 70 mg as a subcutaneous injection once a month is recommended. In patients who display unsatisfactory response to this dose, the dose may be increased to 140 mg once a month, as long as a better effect is proven. Contraindication: Hypersensitivity reactions to the active substance or to any of the excipients according to the composition. Warnings and Precautions: The removable cap contains dry natural rubber latex, which can cause allergic reactions. Severe hypersensitivity reactions including rash, angioedema and anaphylactic reactions were reported with Aimovig since market introduction. Constipation with severe complications may occur when using Aimovig. Patients taking Aimovig should there fore be monitored for signs of severe constipation and be clinically treated accordingly. The simultaneous use of drugs that are associated with reduced gastrointestinal motility may elevate the risk of severe constipation and potential complications. The safety and efficacy of Aimovig in children and adolescents has not been studied. There is no safety information for patients with certain severe cardiovascular diseases. Aimovig should not be used during pregnancy and while breast-feeding, unless this is clearly required. Interactions: Aimovig displayed no influence on the pharmacokinetics of sumatriptan, as well as an oral combination preparation for contraception that contains ethinyl estradiol and norgestimate. Erenumab is not metabolized by cytochrome P450 enzymes, so interactions with substrates, inducers and inhibitors of cytochrome P450 enzymes are unlikely. Adverse Effects: Common: Constipation, itching, muscle cramps, reactions at the injection site (pain, erythema or itching). Pack Sizes: Country-specific. Legal classification: Country-specific. BSS Version: v2.4 Leaflet date: April 2021 Basic Succinct Statement (BSS) AIMOVIG ® (erenumab) 70 mg/mL Solution for injection in a prefilled autoinjector/pen 140 mg/mL Solution for injection in a prefilled autoinjector/pen Version 2.4 Effective date: 05-Oct-2020 Safety Label Change (SLC) Tracking Number: 2020-PSB/GLC-1156-s Document status: Final Property of Novartis Confidential May not be used, divulged, published or otherwise disclosed without the consent of Novartis ≥75 % 72 % Up to 72% of patients achieve ≥ 75% reduction in MMDs at month 6 3